<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Child Adolesc Psychiatry Ment Health</journal-id>
<journal-id journal-id-type="iso-abbrev">Child Adolesc Psychiatry Ment Health</journal-id>
<journal-title-group>
<journal-title>Child and Adolescent Psychiatry and Mental Health</journal-title>
</journal-title-group>
<issn pub-type="epub">1753-2000</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29225671</article-id>
<article-id pub-id-type="pmc">5715991</article-id>
<article-id pub-id-type="publisher-id">196</article-id>
<article-id pub-id-type="doi">10.1186/s13034-017-0196-x</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Tourette syndrome and other neurodevelopmental disorders: a comprehensive review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4906-3200</contrib-id>
<name>
<surname>Cravedi</surname>
<given-names>Elena</given-names>
</name>
<address>
<email>elenacravedi@hotmail.it</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deniau</surname>
<given-names>Emmanuelle</given-names>
</name>
<address>
<email>docteurdeniau@icloud.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giannitelli</surname>
<given-names>Marianna</given-names>
</name>
<address>
<email>giannitelli.m@gmail.com</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xavier</surname>
<given-names>Jean</given-names>
</name>
<address>
<email>jean.xavier@aphp.fr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hartmann</surname>
<given-names>Andreas</given-names>
</name>
<address>
<email>andreas.hartmann@aphp.fr</email>
</address>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Cohen</surname>
<given-names>David</given-names>
</name>
<address>
<phone>+33(0)142162366</phone>
<email>david.cohen@aphp.fr</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Department of Child and Adolescent Psychiatry, </institution><institution>Pitié-Salpêtrière Hospital, APHP, </institution></institution-wrap>83, boulevard de l’hôpital, 75013 Paris, France </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1757 2304</institution-id><institution-id institution-id-type="GRID">grid.8404.8</institution-id><institution>Pediatric Neurology Unit, Children’s Hospital A. Meyer, </institution><institution>University of Firenze, </institution></institution-wrap>Florence, Italy </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2150 9058</institution-id><institution-id institution-id-type="GRID">grid.411439.a</institution-id><institution>Department of Neurology, Reference Centre for Tourette Syndrome, </institution><institution>Pitié-Salpêtrière Hospital, APHP, </institution></institution-wrap>Paris, France </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1955 3500</institution-id><institution-id institution-id-type="GRID">grid.5805.8</institution-id><institution>CNRS UMR 7222, Institute for Intelligent Systems and Robotics, </institution><institution>Sorbonnes Universités, UPMC, </institution></institution-wrap>Paris, France </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>4</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>4</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>11</volume>
<elocation-id>59</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>6</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2017</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">Gilles de la Tourette syndrome (TS) is a complex developmental neuropsychiatric condition in which motor manifestations are often accompanied by comorbid conditions that impact the patient’s quality of life. In the DSM-5, TS belongs to the “neurodevelopmental disorders” group, together with other neurodevelopmental conditions, frequently co-occurring. In this study, we searched the PubMed database using a combination of keywords associating TS and all neurodevelopmental diagnoses. From 1009 original reports, we identified 36 studies addressing TS and neurodevelopmental comorbidities. The available evidence suggests the following: (1) neurodevelopmental comorbidities in TS are the rule, rather than the exception; (2) attention deficit/hyperactivity disorder (ADHD) is the most frequent; (3) there is a continuum from a simple (TS + ADHD or/and learning disorder) to a more complex phenotype (TS + autism spectrum disorder). We conclude that a prompt diagnosis and a detailed description of TS comorbidities are necessary not only to understand the aetiological basis of neurodevelopmental disorders but also to address specific rehabilitative and therapeutic approaches.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Tourette</kwd>
<kwd>Neurodevelopmental disorder</kwd>
<kwd>ADHD</kwd>
<kwd>Autism</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2017</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p id="Par40">According to the DSM-5 classification, Gilles de la Tourette syndrome (TS) is a developmental neuropsychiatric disorder characterised by multiple motor and one or more phonic tics, lasting at least 1 year, with onset during childhood or adolescence [<xref ref-type="bibr" rid="CR1">1</xref>]. A tic is a brief, sudden movement or sound that occurs in an inappropriate context and frequency. The distinguishing characteristics of tic include variability in severity with a waxing and waning course and suppressibility and presence of an anticipatory uncomfortable sensory sensation called a premonitory urge.</p>
<p id="Par41">Although initially considered to be rare, TS is more common than previously expected, with a suggested overall prevalence of 1/200 in children. TS is reported worldwide in all cultures and is more common in males than females (M/F ratio ranging from 1.6:1 to 9:1) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. The aetiopathogenesis of TS is still unclear and more complex than previously perceived, and it involves environmental (infections, perinatal problems, and autoimmunity) and genetic factors that result in a dysfunction of cortico-striato-thalamo-cortical-circuits [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR8">8</xref>].</p>
<p id="Par42">Comorbidities and coexistent pathologies in TS are also common. Hirschtritt et al. in a large clinical based study, analysed 1374 TS patients and found a lifetime prevalence of any psychiatric comorbidity among 85.7% and that 57.7% of the patients involved at least 2 psychiatric disorders [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, recent factor analysis studies have suggested that TS is not a unitary condition but can be subdivided into more homogeneous components that, similar in phenotype, are suitably share the same genetic background [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Because TS comorbidities provide a better understanding of the syndrome not only in terms of classification and aetiopathogenesis but also in terms of outcome, comorbidities are one of the main factors contributing to the psychological and psychosocial impairment observed in TS, often more than the severity of tics [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
<p id="Par43">In the DSM-5, TS belongs to the “neurodevelopmental disorders” group, together with intellectual disabilities, communication disorder, autism spectrum disorder, attention deficit hyperactivity disorder, and specific learning disorder. This group includes conditions that co-occur frequently, typically in the early stages of development, and produce deficits in social, personal, academic and occupational functioning [<xref ref-type="bibr" rid="CR1">1</xref>]. As evidenced by recent literature, TS shares a similar genetic background and risk factors with other neurodevelopmental disorders, that eventually produce similar neuropathological alterations [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. In particular, recent studies have found similar connectivity alterations among ASD, ADHD and TS patients [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Considering all of these findings, the purpose of this article was to provide an extensive review on comorbidity in TS and other neuro-developmental disorders.</p>
</sec>
<sec id="Sec2">
<title>Materials and methods</title>
<p id="Par44">A Medline (PubMed version) search was performed using the following keywords: Tourette and attention deficit hyperactivity disorder (ADHD) or autism or pervasive developmental disorder or Asperger syndrome or learning disorder or Dyslexia or Dysgraphia or Dysorthographia or Dyscalculia or communication disorders or developmental coordination disorder. We included studies and reviews published in English between 1965 and February 2017. We screened all identified studies or reviews by reading the titles and the abstracts. The inclusion criteria for articles were as follows: the analysis of comorbidity between TS and ADHD/autism (ASD)/learning disorders (LD), in term of prevalence, clinical characteristics and prognosis, resulting from cohorts of TS clinical ascertained samples and population-based studies. Duplicate studies were excluded. To identify any potential study missed by our literature research, we applied, as our second step, a cross-referencing search within retained articles. The initial search sorted out 1633 references. After excluding duplicates, the number was reduced to 1009 reports. Comorbidities between TS and communication disorders or developmental coordination disorder were not analysed due to the lack of detailed literature. In total, 36 papers that fulfilled the study criteria were retained. A PRISMA diagram flow-chart, presented in Fig. <xref ref-type="fig" rid="Fig1">1</xref>, summarises the literature selection process and details the primary cause of exclusion. For ease of presentation, we distinguish general population studies (N = 5) and comorbidities in TS clinical-based studies (N = 27) with a specific focus on TS and ASD co-occurrence (N = 6).<fig id="Fig1"><label>Fig. 1</label><caption><p>PRISMA diagram flow-chart of the literature search</p></caption><graphic id="MO1" xlink:href="13034_2017_196_Fig1_HTML"></graphic></fig>
</p>
</sec>
<sec id="Sec3">
<title>Results</title>
<sec id="Sec4">
<title>General population studies</title>
<p id="Par45">The assessment of comorbidity between TS and other neurodevelopmental disorders has been assessed in several general population-based studies (Table <xref ref-type="table" rid="Tab1">1</xref>). One of the first studies was conducted by Comings and Comings in 1990 [<xref ref-type="bibr" rid="CR16">16</xref>] in which they evaluated 3034 students in three schools in Los Angeles and reported an approximately 0.46% frequency of TS (N = 14 individuals). Comorbid ADHD was reported in 10 (70%) of 14 students. Apter et al. [<xref ref-type="bibr" rid="CR17">17</xref>], who screened all recruits in the Israeli Defense Force during a 1-year period, documented 8.3% of ADHD in TS, while the ADHD population point prevalence at that time was 3.9%. The lower prevalence of ADHD in this study is likely due to the age of the subjects (16–17 years old) at the time of evaluation. Wang et al. [<xref ref-type="bibr" rid="CR18">18</xref>] conducted an epidemiological study in a Taiwanese elementary school with 2000 children, highlighting a 0.56% prevalence of TS and a 36% comorbid rate of ADHD. Kadesjo and Gillberg [<xref ref-type="bibr" rid="CR19">19</xref>] examined 435 school-age children and found a 0.15% prevalence of TS. Among the 10 children diagnosed with TS, only 1 had a comorbid ADHD, using the DSM-III criteria and Conners scale. In this study, the rates of other neurodevelopmental disorders were also reported: 22% had comorbid ASD using the autism spectrum screening questionnaire (ASSQ) (5% Asperger, 17% PDD-NOS), 36% had comorbid dyslexia and 24% had a comorbid developmental coordination disorder. Another epidemiological study conducted in Sweden [<xref ref-type="bibr" rid="CR20">20</xref>] on a population of 4479 children measured a 0.6% frequency of TS. In the TS group, the rate of comorbid ADHD, evaluated using the DSM-IV criteria and Conners scale, was 68% (60% combined subtype, 8% hyperactive-impulsive subtype); the rate of ASD was 20% (16% Asperger, 4% PDD-NOS); the rate of dyslexia was 16%; and the rate of developmental coordination disorder was 20%.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Studies based on general population samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author (year)</th><th align="left">N</th><th align="left">Context</th><th align="left">Age</th><th align="left">Prevalence of TS (%)</th><th align="left">Comorbidity</th><th align="left">Scales</th><th align="left">Nationality</th></tr></thead><tbody><tr><td align="left">Comings and Comings (1990) [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="char" char=".">3034</td><td align="left">School</td><td align="left">NS (children)</td><td align="char" char=".">0.46</td><td align="left">ADHD 10/14 (70%)</td><td align="left">NS</td><td align="left">USA</td></tr><tr><td align="left">Apter et al. (1993) [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="char" char=".">2837</td><td align="left">Israeli defense force recruitment</td><td align="left">16–17</td><td align="char" char=".">0.04</td><td align="left">ADHD 8.3%<break></break>OCD 41.7%</td><td align="left">NS</td><td align="left">Israel</td></tr><tr><td align="left">Kadesjo and Gillberg (2000) [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="char" char=".">435</td><td align="left">School</td><td align="left">Mean, 11</td><td align="char" char=".">1.1</td><td align="left">ADHD 1/11 (9%)<break></break>Asperger 1/11 (9%)<break></break>Dyslexia 2/11 (18%)</td><td align="left">DSM III criteria<break></break>Conners<break></break>ASSQ</td><td align="left">Sweden</td></tr><tr><td align="left">Wang et al. (2003) [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="char" char=".">2000</td><td align="left">School</td><td align="left">6–12</td><td align="char" char=".">0.56</td><td align="left">ADHD 36%</td><td align="left">YSTSOBS</td><td align="left">Taiwan</td></tr><tr><td align="left">Khalifa and von Knorring (2006) [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="char" char=".">4479</td><td align="left">School</td><td align="left">7–15</td><td align="char" char=".">0.6</td><td align="left">ADHD 68% (ADHD C 60%, ADHD HI 8%)<break></break>PDD 20% (Asperger 16%, PDD-NOS 4%)<break></break>OCD 16%<break></break>Depression 20%<break></break>Conduct disorder 8%<break></break>Sleep disorder 28%<break></break>DCC 20%<break></break>LD 16%<break></break>ID 16%</td><td align="left">DSM IV criteria<break></break>ASSQ<break></break>CYBOCS<break></break>Conners<break></break>CBCL<break></break>CDI</td><td align="left">Sweden</td></tr></tbody></table><table-wrap-foot><p>ADHD, attention deficit hyperactivity disorder; ASSQ, autism spectrum screening questionnaire; CBCL, child behavior checklist; CDI, children’s depression inventory; CYBOCS, children’s Yale-brown obsessive compulsive scale; DCD, developmental coordination disorder; ID, intellectual disability; LD, learning disorder. NS, not specified; OCD, obsessive compulsive disorder; PDD-NOS, pervasive developmental disorder-not otherwise specified; YSTSOBS, Yale schedule for Tourette syndrome and other behavioral syndromes</p></table-wrap-foot></table-wrap>
</p>
</sec>
<sec id="Sec5">
<title>Clinical-based studies</title>
<sec id="Sec6">
<title>Tourette syndrome and ADHD</title>
<p id="Par46">ADHD is a neurodevelopmental disorder in which a persistent pattern of inattention and hyperactivity-impulsivity interferes with development and has a negative impact on social, academic or occupational functioning [<xref ref-type="bibr" rid="CR1">1</xref>]. The diagnostic criteria and disease definition have changed over time and differ according to the system of classification used: in DSM-5, two dimensions are defined (hyperactivity and impulsivity versus inattention), and a diagnosis can be made if a minimum number of symptoms are scored in only one dimension specifying the subtype (hyperactive-impulsive subtype, combined subtype and predominantly inattentive subtype) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Worldwide prevalence of ADHD in children and adolescents using the DSM-5 broad definition is estimated to be between 5.29 and 7.1% [<xref ref-type="bibr" rid="CR22">22</xref>]. The increased rates of prevalence of ADHD reported in the US over the past several years have led to the impression that ADHD is an “American disorder” and that it is much less prevalent elsewhere. The authors explained this difference primarily using the different methodological characteristics of the studies assessing prevalence rather than cultural or social factors [<xref ref-type="bibr" rid="CR23">23</xref>]. Considering this variability in estimating the prevalence of ADHD, in our review we underline the nationality of the study and the methodology used to assess this comorbidity.</p>
<p id="Par47">ADHD is the most common comorbid condition in patients with TS, as evidenced by the vast literature on the subject, with first association reports dating as early as 1973 [<xref ref-type="bibr" rid="CR24">24</xref>]. 24 studies reported detailed data on ADHD in TS from clinical centres located worldwide (US, Australia, Japan, Iran, Brazil, England, Italy, Germany, Poland, and Denmark) (Table <xref ref-type="table" rid="Tab2">2</xref>). The authors reported a 17–68% prevalence of ADHD in TS cohorts. This variability in comorbidity rate is not attributable to the geographic origin of the study, with US studies reporting similar ADHD comorbidities to studies conducted elsewhere. Of the studies selected, seven used specific rating scales to evaluate comorbid ADHD (e.g., Conners scales, an instrument used to assess ADHD and its most common comorbid problems). Other studies used screening questionnaires to assess behavioural and emotional problems (e.g., child behavior check list-CBCL) or semi-structured diagnostic interview or clinical evaluations based on the DSM criteria. Only 7 studies used a case–control methodology, and 2 [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] differentiated among the three ADHD subtypes.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comorbidities in TS from studies based on clinical samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author (year)</th><th align="left">N</th><th align="left">Age</th><th align="left">Methods used to evaluated comorbidities</th><th align="left">Comorbidity prevalence rate</th><th align="left">Main findings</th><th align="left">Nationality</th></tr></thead><tbody><tr><td align="left">Comings and Comings (1987) [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="left">246</td><td align="left">Mean, 18.2</td><td align="left">DSM III-based questionnaire</td><td align="left">ADHD 48.8%<break></break>ADD 11.8%<break></break>Dyslexia 27%</td><td align="left">TS patients have a significant risk for school problems and increased rate of dyslexia</td><td align="left">USA</td></tr><tr><td align="left">Chee et al. (1994) [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td align="left">50</td><td align="left">Mean, 20.8</td><td align="left">Structured NS interview</td><td align="left">ADHD 32%<break></break>Depression 18%<break></break>Anxiety 30%</td><td align="left">Rate of prevalence of TS and comorbidities in an Australian TS cohort</td><td align="left">Australia</td></tr><tr><td align="left">Abwender et al. (1996) [<xref ref-type="bibr" rid="CR55">55</xref>]</td><td align="left">138</td><td align="left">Children</td><td align="left">NS</td><td align="left">LD 22%</td><td align="left">School difficulties are associated with comorbid ADHD</td><td align="left">USA</td></tr><tr><td align="left">Cardoso et al. (1996) [<xref ref-type="bibr" rid="CR56">56</xref>]</td><td align="left">32</td><td align="left">Mean, 24</td><td align="left">DSM IV criteria</td><td align="left">ADHD NS 63%<break></break>OCD 44%<break></break>Sleep disorders 53%<break></break>Depression 31%<break></break>Impulse control deficit 28%</td><td align="left">Rate of prevalence of TS and comorbidities in a Brazilian TS cohort</td><td align="left">Brazil</td></tr><tr><td align="left">Schuerholz et al. (1996) [<xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">65</td><td align="left">6–14</td><td align="left">NS</td><td align="left">LD 23%</td><td align="left">LD is strongly correlated to the presence of ADHD</td><td align="left">USA</td></tr><tr><td align="left">Yeates et al. (1996) [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="left">70</td><td align="left">6–18</td><td align="left">WRAT-R<break></break>WCST<break></break>HRB<break></break>HRB<break></break>WISC-R</td><td align="left">Deficit in arithmetic 14/70 (20%)<break></break>Deficit in reading (14%)<break></break>General academic deficit (29%)</td><td align="left">TS children classified in different learning disability subtypes reveal significant differences in neuropsychological functioning</td><td align="left">USA</td></tr><tr><td align="left">Wodrich et al. (1997) [<xref ref-type="bibr" rid="CR58">58</xref>]</td><td align="left">33</td><td align="left">Children</td><td align="left">DSM III criteria</td><td align="left">ADHD NS 55%<break></break>Depression 73%<break></break>Conduct problems 18%</td><td align="left">Prevalence and manifestations of comorbidities of TS patients in psychiatry practice are not identical to those reported in the literature</td><td align="left">USA</td></tr><tr><td align="left">Kano et al. (1998) [<xref ref-type="bibr" rid="CR59">59</xref>]</td><td align="left">64</td><td align="left">Mean, 17.4</td><td align="left">DSM III-R criteria</td><td align="left">ADHD NS 17.2%<break></break>OCD 62.5%</td><td align="left">Rate of coprolalia in Japan is higher than the previously reported rate, and TS is often associated with developmental disorders</td><td align="left">Japan</td></tr><tr><td align="left">Freeman et al. (2000) [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="left">3500</td><td align="left">NS</td><td align="left">DSM III/IV criteria</td><td align="left">ADHD HI 7%<break></break>ADHD C 51%<break></break>ADHD PI 37%<break></break>PDD 4.6%<break></break>OCD 22.3%<break></break>Mood disorder 16.9%<break></break>Anxiety disorder 16.8%<break></break>ID 3.4%<break></break>Anger 27.6%<break></break>Sleep problem 17.8%</td><td align="left">ADHD is associated with an earlier diagnosis of TS and a higher rate of comorbidities (with the exception of anxiety disorders)<break></break>One-third of TS + ADHD cases have LD, 26% have social skill deficits, and 39% have problems controlling anger</td><td align="left">International database (author from Canada)</td></tr><tr><td align="left">Teive et al. (2001) [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="left">44 CTD (75% TS)</td><td align="left">3–60</td><td align="left">DSM IV criteria</td><td align="left">ADHD 38.6%<break></break>OCD 59.1%<break></break>Affective disorders 11%<break></break>Anxiety disorder 9%<break></break>LD 14%<break></break>Sleep disorder 9%<break></break>Behavioural disorder 7%</td><td align="left">Rate of comorbidities in a Brazilian clinical cohort</td><td align="left">Brazil</td></tr><tr><td align="left">Burd et al. (2005) [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="left">5450</td><td align="left">NS</td><td align="left">DSM IV criteria</td><td align="left">LD 22.7%<break></break>ADHD NS 58%</td><td align="left">In TS + LD, 80.2% patients also have ADHD and in the TS − LD group, 51.3% have ADHD; 31% of subjects with ADHD have also a diagnosis of LD</td><td align="left">TIC international database (author from USA)</td></tr><tr><td align="left">Saccomani et al. (2005) [<xref ref-type="bibr" rid="CR60">60</xref>]</td><td align="left">48</td><td align="left">Mean, 11.2</td><td align="left">DSM IV criteria</td><td align="left">ADHD ns 43.8%<break></break>OCD 54.2%<break></break>Anxiety disorders 2.1%<break></break>Sleep problems 27.1%<break></break>Mood disorders 18.8%</td><td align="left">Rate of comorbidities and clinical features of an Italian clinical cohort</td><td align="left">Italy</td></tr><tr><td align="left">Termine et al. (2006) [<xref ref-type="bibr" rid="CR61">61</xref>]</td><td align="left">17</td><td align="left">Mean, 11.4</td><td align="left">CBCL<break></break>Conners<break></break>SAFA<break></break>K-SADS<break></break>YGTSS</td><td align="left">ADHD ns 11.8%<break></break>ADHD ns + OCD 23.5%<break></break>OCD 41.2%</td><td align="left">TS patients have a high prevalence of ADHD and OCD compared with controls</td><td align="left">Italy</td></tr><tr><td align="left">Janik et al. (2007) [<xref ref-type="bibr" rid="CR62">62</xref>]</td><td align="left">126</td><td align="left">Mean, 7.6</td><td align="left">NS</td><td align="left">ADHD ns 59%</td><td align="left">Rate of comorbidities and clinical features of a Polish clinical cohort</td><td align="left">Poland</td></tr><tr><td align="left">Roessner et al. (2007) [<xref ref-type="bibr" rid="CR63">63</xref>]</td><td align="left">5060 (TIC database)</td><td align="left">NS</td><td align="left">DSM IV criteria</td><td align="left">ADHD ns 61.2%</td><td align="left">Comorbid ADHD is associated with high rates of externalising and internalising problems</td><td align="left">International database (author from Germany)</td></tr><tr><td align="left">Robertson et al. (2008) [<xref ref-type="bibr" rid="CR64">64</xref>]</td><td align="left">410</td><td align="left">3–59</td><td align="left">DSM IV criteria<break></break>NHIS</td><td align="left">ADHD 56% (230/410)</td><td align="left">Factor analytic study. TS can be disaggregated into more homogeneous symptom components</td><td align="left">USA</td></tr><tr><td align="left">Ghanizadeh et al. (2009) [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">35</td><td align="left">Mean, 11.8</td><td align="left">CBCL<break></break>K-SADS<break></break>YGTSS</td><td align="left">ASD 2.9%<break></break>ADHD 68.6%</td><td align="left">Rate of comorbidities and clinical features of an Iranian clinical cohort</td><td align="left">Iran</td></tr><tr><td align="left">Gorman et al. (2010) [<xref ref-type="bibr" rid="CR66">66</xref>]</td><td align="left">65</td><td align="left">Mean, 18</td><td align="left">CBCL<break></break>K-SADS<break></break>CGAS<break></break>CYBOCS<break></break>Vineland<break></break>YGTSS</td><td align="left">ADHD 43%<break></break>LD 27%<break></break>OCD 25%<break></break>Conduct disorder 15%<break></break>Major depressive disorder 40%</td><td align="left">Tic and ADHD severity are associated with a poorer psychosocial outcome</td><td align="left">USA</td></tr><tr><td align="left">Specht et al. (2011) [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="left">126 (93.7% TS)</td><td align="left">Mean, 11.7</td><td align="left">ADIS-RLV<break></break>CBCL<break></break>CGI-S<break></break>YGTSS<break></break>CGAS</td><td align="left">ADHD ns 26%<break></break>Social phobia 21%<break></break>Anxiety disorder 20%<break></break>OCD 19%</td><td align="left">In a sample of youth seeking treatment for a chronic tic disorder, ADHD is much lower than in clinically ascertained case series</td><td align="left">USA</td></tr><tr><td align="left">Lebowitz et al. (2012) [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="left">158 CTD (143 TS)</td><td align="left">6–14.5</td><td align="left">Conners<break></break>ASQ-P<break></break>DISC IV<break></break>CYBOCS<break></break>MASC<break></break>YGTSS<break></break>CGAS</td><td align="left">ADHD 38.6%<break></break>OCD 53.8%<break></break>ADHD + OCD 24.1%</td><td align="left">TD with comorbid ADHD is associated with higher psychosocial stress and more externalising behaviours</td><td align="left">USA</td></tr><tr><td align="left">Rizzo et al. (2014) [<xref ref-type="bibr" rid="CR67">67</xref>]</td><td align="left">92</td><td align="left">7–17</td><td align="left">Conners<break></break>DSM IV/V criteria<break></break>CBCL<break></break>MASC<break></break>CDI<break></break>YQLI-RV<break></break>WISC-III</td><td align="left">ADHD 22.2%<break></break>ADHD + OCD 6.5%<break></break>OCD 21.5%</td><td align="left">TS + comorbidity patients have overrepresented affective and anxiety symptoms</td><td align="left">Italy</td></tr><tr><td align="left">Byler (2015) [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="left">482<break></break>Two evaluation</td><td align="left">Mean, 9.8</td><td align="left">NS</td><td align="left">ADHD 40% (first evaluation) + 21% (second evaluation)<break></break>LD 5.4%<break></break>Asperger 3% (first) + 2.1% (second)<break></break>OCD 17% (first) + 14% (second evaluation)<break></break>Survey:<break></break>ADHD ns 41%, OCD 42%, LD 26.5%</td><td align="left">More than 40% of TS patients continued to report ADHD or OCD as adults</td><td align="left">USA</td></tr><tr><td align="left">Hirschtritt et al. (2015) [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td align="left">1374</td><td align="left">Mean, 19.1</td><td align="left">K-SADS<break></break>DSM-IV structured interview</td><td align="left">ADHD ns 54.3%<break></break>OCD 66%<break></break>Mood disorders 30%<break></break>Disruptive behaviour 30%<break></break>Anxiety 32%</td><td align="left">ADHD began before tic onset and increased the presence of other comorbidities</td><td align="left">USA<break></break>Canada<break></break>Great Britain<break></break>Netherlands</td></tr><tr><td align="left">Eapen et al. (2016) [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="left">83</td><td align="left">N = 43 &lt; 18 <break></break>N = 40 &gt; 18</td><td align="left">NHIS<break></break>YGTSS<break></break>HR-QoL</td><td align="left">ADHD ns 21%<break></break>LD 24%<break></break>ASD 15%<break></break>OCD 35%<break></break>Anxiety disorder 45%<break></break>Depressive disorders 33%<break></break>Conduct disorder 4.8%</td><td align="left">Presence of comorbidities and ADHD, in particular, has a greater impact on quality of life</td><td align="left">Australia</td></tr><tr><td align="left">Huisman-van Dijk et al. (2016) [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td align="left">225</td><td align="left">6–72</td><td align="left">Conners<break></break>AQ<break></break>SCID-I<break></break>CYBOCS<break></break>YGTSS</td><td align="left">ADHD 26%<break></break>ASD 20%<break></break>OCD 35.9%</td><td align="left">Exploratory factor analyses (EFA) reveal a five-factor structure</td><td align="left">Germany</td></tr><tr><td align="left">Sambrani et al. (2016) [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="left">1032 CTD (978 TS)</td><td align="left">N = 529 &lt; 18 <break></break>N = 503 &gt; 18</td><td align="left">DSM IV criteria</td><td align="left">ADHD 45%<break></break>Hyperactivity 28.4%<break></break>Inattention 39.4%<break></break>OCD 10%<break></break>Sleeping problems 27%<break></break>Anxiety 31%<break></break>Depression 23%</td><td align="left">Comorbid ADHD reduces the patients’ ability for tic suppression</td><td align="left">Germany</td></tr></tbody></table><table-wrap-foot><p>ADD, attention deficit disorder; ADHD, attention deficit/hyperactivity disorder; ADHD C, ADHD combined; ADHD HI, ADHD hyperactive; ADHD PI, ADHD predominantly inattentive; ADHD HADIS-RLV, anxiety disorders interview schedule for DSMIV: research and lifetime version for children and parents; ASD, autism spectrum disorder; ASQ, autism screening questionnaire; ASQ-P, Conners abbreviated symptom questionnaire-parent; ASSQ, autism spectrum screening questionnaire; AQ, autism-spectrum quotient; CBCL, child behavior checklist; CDI, children’s depression inventory; CGAS, children’s global assessment scale; CGI-S, clinical global impression-severity scale; CTD, chronic tic disorder; CYBOCS, children’s Yale-brown obsessive compulsive scale; DISC IV, diagnostic interview schedule for children; GTS-QOL, Gilles de la Tourette syndrome-quality of life scale; HRB, Halstead-retain neuropsychological test battery; ID, intellectual disability; K-SADS, Kiddie schedule for affective disorders and schizophrenia; LD, learning disorder; MASC, multidimensional anxiety scale for children; NHIS, national hospital interview schedule; NS, not specified; OCD, obsessive compulsive disorder; PDD, pervasive developmental disorder; PIC, personality inventory for children; SAFA, self administrated psychiatric scales for children and adolescents; SCID, structured clinical interview; STSS, Shapiro Tourette syndrome severity; TS, Tourette syndrome; WCST, Wisconsin card sorting test; WISC-R, Wechsler intelligence scale for children-revised; WRAT-R, wide range achievement test-revised; YGTSS, Yale global tic severity scale; YQLI-RV, youth quality of life-research; YSTSOBS, Yale schedule for Tourette’s syndrome and other behavioral syndromes</p></table-wrap-foot></table-wrap>
</p>
<p id="Par48">The presence of comorbid ADHD appears to be one of the most important determinants of quality of life and, in the presence of comorbid ADHD, the rates of other comorbidities (e.g., rage, symptoms of seasonal affective disorder, sleep disturbances and depressive symptoms) are significantly higher than in ‘TS only’ patients and contributes to poorer psychosocial outcome and educational problems [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR27">27</xref>–<xref ref-type="bibr" rid="CR29">29</xref>]. Comorbid ADHD has an important effect on prognosis in TS adult patients: Byler et al. [<xref ref-type="bibr" rid="CR30">30</xref>] conducted a two-step analysis of a clinical cohort (using revision charts and then telephone surveys) finding that in adult life, more than 80% of TS patients reported persisting motor and vocal tics as mild or inexistent, but that more than 40% continued to report some type of comorbidity, with ADHD and OCD most commonly reported.</p>
<p id="Par49">All these findings were confirmed in a large study conducted using the international “TIC” (Tourette Syndrome International Consortium) database containing 6805 TS patients from 22 countries [<xref ref-type="bibr" rid="CR25">25</xref>]. The prevalence of ADHD in TS was stated to be 55% using the DSM-IV criteria. Regarding the preliminary data on 153 sequential cases, the authors could differentiate between ADHD subtypes, and they found the relative proportions of the three ADHD subtypes to be consistent with other studies on ADHD (7% fit the hyperactive-impulsive subtype, 51% fit the combined subtype and 37% fit the predominantly inattentive subtype). Comorbidity with ADHD was associated with earlier diagnosis and a higher rate of other comorbidities with the exception of anxiety disorder. Behavioural difficulties in TS with ADHD were found to be associated with the combined or hyperactive subtypes. Moreover, the authors found that comorbid ADHD was associated with a higher rate of developmental coordination disorder (14% in TS plus ADHD group versus 7% in TS without ADHD group).</p>
</sec>
<sec id="Sec7">
<title>Tourette syndrome and learning disorders</title>
<p id="Par50">According to the DSM-5, LD are developmental disorders that begin by school age and impede the ability to learn or use specific academic skills (e.g., reading, writing, or arithmetic), which constitute the foundation for other academic learning [<xref ref-type="bibr" rid="CR1">1</xref>]. The prevalence of LD in the general population is estimated to range between 5 and 9% [<xref ref-type="bibr" rid="CR31">31</xref>]. School problems are frequently reported in TS children. Comings and Comings [<xref ref-type="bibr" rid="CR32">32</xref>], summarising the different areas that impact on TS patients and cause school problems, individuated the most important as follows: motor tics that interfere in reading and writing; comorbidity with ADHD; deficits in socialization and rejection by peers and/or the teacher; medications that can cause cognitive blunting and contribute to learning problems; and the presence of specific LD.</p>
<p id="Par51">The prevalence of LD in TS samples is only based on 10 studies (Table <xref ref-type="table" rid="Tab2">2</xref>) including 4 that were specifically addressed to evaluate LD in TS patients; in the other papers, the focus was mainly on comorbidities in general. With the exception of 2 studies reporting a 5.4 and 14% prevalence of LD [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], the other studies defined a more homogeneous prevalence (approximately 20–30%) of LD in TS patients (Table <xref ref-type="table" rid="Tab2">2</xref>). Among the 9 studies selected, the diagnosis of LD was confirmed using the DSM criteria with only 2 studies utilising specific instruments for the assessment of LD.</p>
<p id="Par52">Comings and Comings [<xref ref-type="bibr" rid="CR32">32</xref>], evaluating a population of TS patients using a specific questionnaire for reading problems, found dyslexia in 26.8% of TS patients compared with 4.2% of the controls. Yeates et al. [<xref ref-type="bibr" rid="CR34">34</xref>] examined the neuropsychological profiles of 70 TS children and classified them into four groups based on their pattern of performance on the wide range achievement test-revised (Table <xref ref-type="table" rid="Tab2">2</xref>). Burd et al. [<xref ref-type="bibr" rid="CR35">35</xref>], analysing the “TIC” database (5450 subjects), established a 22.7% prevalence of LD using the DSM criteria and compared TS subjects with comorbid learning disability and TS only subjects. The “TS plus LD” group showed an increased proportion of males, an earlier age of onset of TS, an earlier age at the time of first evaluation and diagnosis, a higher rate of perinatal problems, more severe tics and a higher rate of ADHD (80%).</p>
</sec>
<sec id="Sec8">
<title>Tourette syndrome and other comorbidities</title>
<p id="Par53">Although this is not the focus of this review, we summarise the main results regarding the rates of other comorbidities rather than neurodevelopmental disorders obtained from the papers we selected. Obsessive compulsive disorder (OCD) together with ADHD is the most frequent comorbidity in TS patients with rates ranging from 10 to 60% [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. In most studies, as demonstrated for ADHD, comorbidity with OCD represented one of the main determinants in terms of psychosocial and psychological outcomes in TS patients. Other comorbid conditions often reported in TS patients are depression (ranging from 11 to 73%), anxiety (2–45%), sleeping problems (9–53%) and externalising disorders or behaviours, such as conduct problems and rage attacks (5–30%). With the exception of anxiety, which is still debatable, these comorbidities appear to be highly associated with the presence of ADHD. Of the studies selected, only one [<xref ref-type="bibr" rid="CR36">36</xref>] evaluated the presence of intellectual disability at a rate of 3.4%.</p>
</sec>
</sec>
<sec id="Sec9">
<title>Tourette syndrome and autism spectrum disorder</title>
<p id="Par54">ASD, as classified by the DSM-5, is a neurodevelopmental disorder characterised by persistent deficits in social communication and social interaction across multiple contexts together with restricted and repetitive patterns of behaviour and interests or activities [<xref ref-type="bibr" rid="CR1">1</xref>]. In a 2012 review, the global prevalence of ASD was estimated in a median of 62 cases per 10,000 people [<xref ref-type="bibr" rid="CR37">37</xref>]. Tic disorders in ASD patients were first described in single case reports and in small case series [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR41">41</xref>]. Only few studies have analysed the prevalence of comorbid TS in large ASD clinical samples [<xref ref-type="bibr" rid="CR42">42</xref>–<xref ref-type="bibr" rid="CR44">44</xref>]. The reported TS rate in ASD population varies from 2.6 to 11% (Table <xref ref-type="table" rid="Tab3">3</xref>). A transient association between TS and ASD has also been reported in a case series: Zappella described 12 young patients with early-onset TS comorbidity with reversible autistic behaviours. However, comorbidities between TS and ASD in most cases persist over time, and cases of ASD in TS samples have also been described. Clinical studies from TS samples highlight a prevalence of ASD in TS patients that can vary from 2.9 to 20% [<xref ref-type="bibr" rid="CR11">11</xref>].<table-wrap id="Tab3"><label>Table 3</label><caption><p>Studies reporting ASD in TS samples and TS in ASD samples</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author (year)</th><th align="left">Type of study</th><th align="left">N</th><th align="left">Age</th><th align="left">Comorbidity rate</th><th align="left">Scales</th><th align="left">Country</th></tr></thead><tbody><tr><td align="left" colspan="7">TS in ASD samples</td></tr><tr><td align="left"> Canitano and Vivanti (2007) [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="left">Clinical cohort of ASD</td><td align="char" char=".">105</td><td align="left">Mean, 12</td><td align="left">11% TS</td><td align="left">DSM IV criteria<break></break>YGTSS<break></break>Vineland ABS</td><td align="left">Italy</td></tr><tr><td align="left"> Baron-Cohen (1999) [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="left">Clinical cohort of ASD</td><td align="char" char=".">458</td><td align="left">Mean, 11.1</td><td align="left">6.2% TS</td><td align="left">NHIS<break></break>YGTSS<break></break>DSM III-IV criteria</td><td align="left">England</td></tr><tr><td align="left"> Kano et al. (1987) [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="left">Clinical cohort of ASD</td><td align="char" char=".">76</td><td align="left">NS</td><td align="left">2.6% TS</td><td align="left">NS</td><td align="left">Japan</td></tr><tr><td align="left" colspan="7">ASD in TS samples</td></tr><tr><td align="left"> Burd et al. (2009) [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="left">Clinical cohort of TS</td><td align="char" char=".">7288</td><td align="left">NS</td><td align="left">4.6% ASD</td><td align="left">DSM IV criteria</td><td align="left">Tic international database (author from US)</td></tr><tr><td align="left"> Ghanizadeh et al. (2009) [<xref ref-type="bibr" rid="CR65">65</xref>]</td><td align="left">Clinical cohort of TS</td><td align="char" char=".">35</td><td align="left">Mean, 11.8</td><td align="left">2.9% ASD<break></break>68.6% ADHD</td><td align="left">CBCL<break></break>K-SADS<break></break>YGTSS</td><td align="left">Iran</td></tr><tr><td align="left"> Huisman-van Dijk et al. (2016) [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td align="left">Clinical cohort of TS</td><td align="char" char=".">225</td><td align="left">6–72</td><td align="left">26% ADHD<break></break>20% ASD<break></break>35.9% OCD</td><td align="left">Conners<break></break>AQ<break></break>SCID-I<break></break>Y-BOCS<break></break>YGTSS</td><td align="left">Germany</td></tr></tbody></table><table-wrap-foot><p>AQ, autism-spectrum quotient; ASD, autism spectrum disorder; CBCL, child behavior checklist; CYBOCS, children’s Yale-brown obsessive compulsive scale; K-SADS, Kiddie schedule for affective disorders and schizophrenia; NHIS, national hospital interview schedule; NS, not specified; OCD, obsessive compulsive disorder; SCID, structured clinical interview; Vineland ABS, Vineland adaptive behavior scales; Y-BOCS, Yale-brown obsessive–compulsive scale; YGTSS, Yale global tic severity scale</p></table-wrap-foot></table-wrap>
</p>
<p id="Par55">From the 6 studies found in the literature (Table <xref ref-type="table" rid="Tab3">3</xref>), only one assessed the comorbidity between TS and ASD using a specific scale for autism (e.g., autism-spectrum quotient, AQ; childhood autism rating scale, CARS). Among the abovementioned clinical sample-based studies, the largest clinical sample of TS patients reported the most accurate characterisation of ASD comorbidity in our opinion [<xref ref-type="bibr" rid="CR45">45</xref>]. Analysing 7288 patients from the Tourette Syndrome International Database Consortium Registry, the authors found that 334 (4.6%) TS individuals had comorbid ASD. In patients with TS and comorbid ASD, the rate of additional comorbidities increased considerably (98.8% TS + ASD patients had one or more comorbidities compared to 13.2% in the participants with TS only). A possible limitation of this work is represented by the fact that the diagnosis of ASD was confirmed using a structured reporting format based on the DSM criteria instead of an evaluation using specific instruments.</p>
</sec>
</sec>
<sec id="Sec10">
<title>Discussion</title>
<p id="Par56">A peculiar feature of TS, which is now classified among the DSM-5 neurodevelopmental disorders, is represented by the frequent association with different comorbidities occurring in the majority of patients. In this paper, we reviewed the literature on comorbidity between TS and other DSM-5 neurodevelopmental disorders, focussing on ADHD, autism spectrum disorders and learning disabilities. Communication disorders and developmental coordination disorders were not included in this review because the scientific literature on this topic is still lacking. The available evidence suggests that neurodevelopmental comorbidities in TS are the rule rather than the exception. The high rate of neurodevelopmental comorbidities is found in general population studies as well as in clinical sample studies (Tables <xref ref-type="table" rid="Tab2">2</xref>, <xref ref-type="table" rid="Tab3">3</xref>). Among these neurodevelopmental comorbidities, ADHD is by far the most frequent. Considering the literature analysed, ADHD is one of the main determinants in terms of quality of life, psychosocial and psychological outcome. We found only few studies in which the abovementioned association distinguished the various ADHD subtypes. These studies demonstrated high rates of association with the combined and prevalent inattentive subtypes. Although we are aware that searches on TS and ASD as well as TS and LD produced few publications, they confirm an association between these disorders and support the idea of a continuum between simple TS without neurodevelopmental comorbidities and more complexes phenotypes (TS + ADHD + LD and TS + ASD). Other limitations of this review are the small number of studies or samples regarding several neurodevelopmental comorbidities (e.g., ASD) and the frequent lack of adequate diagnostic instruments for assessing patients and defining comorbidities. In particular, a further bias caused by the different quality of the studies evaluated, could lie in the absence of specific assessments performed by clinicians expert in the field, thus resulting in a possible overestimation of the rates of comorbidities, such LD and ASD [<xref ref-type="bibr" rid="CR46">46</xref>]. Moreover, we are aware that the variability of the age of the populations investigated is a factor affecting the prevalence rate. However, the current results favour the inclusion of TS among neurodevelopmental disorders as a DSM-5 group of conditions. The inclusion criteria were based on prevalence, clinical characteristics and prognosis. Interestingly, TS not only co-occurs often with other neurodevelopmental disorders, but it is also likely linked through common genetic background and common risk factors, as evidenced by the recent literature [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. Figure <xref ref-type="fig" rid="Fig2">2</xref> provides a graphical representation of this spectrum of neurodevelopmental comorbidities based on the data obtained in TS clinical samples and according to frequency and age of onset. In this sense, it appears advisable to explore clusters of neurodevelopmental problems rather than screen them separately. This is consistent with the concept of “ESSENCE” (early symptomatic syndromes eliciting neurodevelopmental clinical examinations), a term coined by Gillberg to refer to children with major difficulties in one or more of the following fields: general development, communication and language, social inter-relatedness, motor coordination, attention, activity, behaviour, mood, and sleep [<xref ref-type="bibr" rid="CR49">49</xref>].<fig id="Fig2"><label>Fig. 2</label><caption><p>Co-occurrence of neurodevelopmental disorders in TS clinical samples according to age of onset and frequency</p></caption><graphic id="MO2" xlink:href="13034_2017_196_Fig2_HTML"></graphic></fig>
</p>
<p id="Par57">From an empirical research perspective, additional studies that specifically address the comorbidity between TS and other neurodevelopmental disorders, use appropriate assessment instruments and design and do not neglect certain areas are warranted. First, studies evaluating the co-occurrence of all neurodevelopmental disorders as classified in DSM-5 (thus also including developmental coordination disorder, communication disorders and intellectual disabilities) in the same TS patients’ sample and in a developmental perspective are needed. Second, additional studies should address ADHD for a better characterization of comorbid ADHD into different subtypes. Similarly, subtypes of LD should be determined, using objective neuropsychological assessment of both attention and executive functions or specific learning investigations, such as literacy or calculation assessments. Third, from the literature analysed, it appears that most patients with ASD found in TS samples correspond to patients previously classified in DSM-IV as PDD-NOS or to patients affected by MCDD (multiple complex developmental disorder), a term proposed by Cohen et al. in 1986 [<xref ref-type="bibr" rid="CR50">50</xref>] to refer to a group of children with atypical development. In this sense, more detailed studies focussing on comorbid ASD using developmental and dimensional perspectives are recommended.</p>
<p id="Par58">In conclusion, a prompt diagnosis of comorbidities in TS patients and a characterisation of them in a more comprehensive approach are important not only to understand the aetiological basis of neurodevelopmental disorders but also, as clinical relevance, for a prompt definition of rehabilitative and therapeutic approaches. These include pharmacotherapy [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>] and, equally importantly, cognitive-behavioural therapy and social interventions [<xref ref-type="bibr" rid="CR53">53</xref>].</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>ADHD</term>
<def>
<p id="Par2">attention deficit/hyperactivity disorder</p>
</def>
</def-item>
<def-item>
<term>ADIS-RLV</term>
<def>
<p id="Par3">anxiety disorders interview schedule for DSMIV: research and lifetime version for children and parents</p>
</def>
</def-item>
<def-item>
<term>ASD</term>
<def>
<p id="Par4">autism spectrum disorder</p>
</def>
</def-item>
<def-item>
<term>ASQ</term>
<def>
<p id="Par5">autism screening questionnaire</p>
</def>
</def-item>
<def-item>
<term>ASQ-P</term>
<def>
<p id="Par6">Conners abbreviated symptom questionnaire-parent</p>
</def>
</def-item>
<def-item>
<term>AQ</term>
<def>
<p id="Par7">autism-spectrum quotient</p>
</def>
</def-item>
<def-item>
<term>ASSQ</term>
<def>
<p id="Par8">autism spectrum screening questionnaire</p>
</def>
</def-item>
<def-item>
<term>CBCL</term>
<def>
<p id="Par9">child behavior checklist</p>
</def>
</def-item>
<def-item>
<term>CDI</term>
<def>
<p id="Par10">children’s depression inventory</p>
</def>
</def-item>
<def-item>
<term>CGAS</term>
<def>
<p id="Par11">children’s global assessment scale</p>
</def>
</def-item>
<def-item>
<term>CGI-S</term>
<def>
<p id="Par12">clinical global impression-severity scale</p>
</def>
</def-item>
<def-item>
<term>CTD</term>
<def>
<p id="Par13">chronic tic disorder</p>
</def>
</def-item>
<def-item>
<term>CYBOCS</term>
<def>
<p id="Par14">children’s Yale-brown obsessive compulsive scale</p>
</def>
</def-item>
<def-item>
<term>DCD</term>
<def>
<p id="Par15">developmental coordination disorder</p>
</def>
</def-item>
<def-item>
<term>DISC IV</term>
<def>
<p id="Par16">diagnostic interview schedule for children</p>
</def>
</def-item>
<def-item>
<term>GTS-QOL</term>
<def>
<p id="Par17">Gilles de la Tourette syndrome-quality of life scale</p>
</def>
</def-item>
<def-item>
<term>HRB</term>
<def>
<p id="Par18">Halstead-retain neuropsychological test battery</p>
</def>
</def-item>
<def-item>
<term>ID</term>
<def>
<p id="Par19">intellectual disability</p>
</def>
</def-item>
<def-item>
<term>LD</term>
<def>
<p id="Par20">learning disorder</p>
</def>
</def-item>
<def-item>
<term>K-SADS</term>
<def>
<p id="Par21">Kiddie schedule for affective disorders and schizophrenia</p>
</def>
</def-item>
<def-item>
<term>MASC</term>
<def>
<p id="Par22">multidimensional anxiety scale for children</p>
</def>
</def-item>
<def-item>
<term>NHIS</term>
<def>
<p id="Par23">national hospital interview schedule</p>
</def>
</def-item>
<def-item>
<term>NS</term>
<def>
<p id="Par24">not specified</p>
</def>
</def-item>
<def-item>
<term>OCD</term>
<def>
<p id="Par25">obsessive compulsive disorder</p>
</def>
</def-item>
<def-item>
<term>PDD-NOS</term>
<def>
<p id="Par26">pervasive developmental disorder-not otherwise specified</p>
</def>
</def-item>
<def-item>
<term>PIC</term>
<def>
<p id="Par27">personality inventory for children</p>
</def>
</def-item>
<def-item>
<term>SAFA</term>
<def>
<p id="Par28">self administrated psychiatric scales for children and adolescents</p>
</def>
</def-item>
<def-item>
<term>SCID</term>
<def>
<p id="Par29">structured clinical interview</p>
</def>
</def-item>
<def-item>
<term>STSS</term>
<def>
<p id="Par30">Shapiro Tourette syndrome severity</p>
</def>
</def-item>
<def-item>
<term>TS</term>
<def>
<p id="Par31">Tourette syndrome</p>
</def>
</def-item>
<def-item>
<term>Vineland ABS</term>
<def>
<p id="Par32">Vineland adaptive behavior scales</p>
</def>
</def-item>
<def-item>
<term>WCST</term>
<def>
<p id="Par33">Wisconsin card sorting test</p>
</def>
</def-item>
<def-item>
<term>WISC-R</term>
<def>
<p id="Par34">Wechsler intelligence scale for children-revised</p>
</def>
</def-item>
<def-item>
<term>WRAT-R</term>
<def>
<p id="Par35">wide range achievement test-revised</p>
</def>
</def-item>
<def-item>
<term>Y-BOCS</term>
<def>
<p id="Par36">Yale-brown obsessive–compulsive scale</p>
</def>
</def-item>
<def-item>
<term>YGTSS</term>
<def>
<p id="Par37">Yale global tic severity scale</p>
</def>
</def-item>
<def-item>
<term>YQLI-RV</term>
<def>
<p id="Par38">youth quality of life-research</p>
</def>
</def-item>
<def-item>
<term>YSTSOBS</term>
<def>
<p id="Par39">Yale schedule for Tourette’s syndrome and other behavioral syndromes</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Authors’ contributions</title>
<p>EC: manuscript conception and preparation, manuscript submission; ED and MG: manuscript conception; JX and AH: manuscript conception and preparation; DC: manuscript conception; writing and review of the draft. All authors read and approved the final manuscript.</p>
<sec id="FPar1">
<title>Acknowledgements</title>
<p id="Par59">Not applicable.</p>
</sec>
<sec id="FPar2">
<title>Competing interests</title>
<p id="Par60">The authors declare that they have no competing interests.</p>
</sec>
<sec id="FPar3">
<title>Availability of data and materials</title>
<p id="Par61">
<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link>.</p>
</sec>
<sec id="FPar4">
<title>Consent for publication</title>
<p id="Par62">Not applicable.</p>
</sec>
<sec id="FPar5">
<title>Ethics approval and consent to participate</title>
<p id="Par63">Not applicable.</p>
</sec>
<sec id="FPar6">
<title>Funding</title>
<p id="Par64">Not applicable.</p>
</sec>
<sec id="FPar7">
<title>Publisher’s Note</title>
<p id="Par65">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>DSM-V
          <year>2013</year>
<publisher-loc>St. Louis</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robertson</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and coexistent psychopathologies</article-title>
<source/>Lancet Psychiatry
          <year>2015</year>
<volume>2</volume>
<fpage>68</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1016/S2215-0366(14)00132-1</pub-id>
<pub-id pub-id-type="pmid">26359614</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharf</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Gauvin</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Population prevalence of Tourette syndrome: a systematic review and meta-analysis</article-title>
<source/>Mov Disord
          <year>2015</year>
<volume>30</volume>
<fpage>221</fpage>
<lpage>228</lpage>
<pub-id pub-id-type="doi">10.1002/mds.26089</pub-id>
<pub-id pub-id-type="pmid">25487709</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tagwerker Gloor</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Walitza</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Tic disorders and Tourette syndrome: current concepts of etiology and treatment in children and adolescents</article-title>
<source/>Neuropediatrics
          <year>2016</year>
<volume>47</volume>
<fpage>84</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1055/s-0035-1570492</pub-id>
<pub-id pub-id-type="pmid">26829367</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forde</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Kanaan</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Widomska</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>TS-EUROTRAIN: a European-wide investigation and training network on the etiology and pathophysiology of Gilles de la Tourette syndrome</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>384</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00384</pub-id>
<pub-id pub-id-type="pmid">27601976</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worbe</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Marrakchi-Kacem</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lecomte</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome</article-title>
<source/>Brain
          <year>2015</year>
<volume>138</volume>
<fpage>472</fpage>
<lpage>482</lpage>
<pub-id pub-id-type="doi">10.1093/brain/awu311</pub-id>
<pub-id pub-id-type="pmid">25392196</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Georgitsi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Willsey</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Mathews</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The genetic etiology of Tourette syndrome: large-scale collaborative efforts on the precipice of discovery</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>351</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00351</pub-id>
<pub-id pub-id-type="pmid">27536211</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Buttiglione</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>The role of immune mechanisms in Tourette syndrome</article-title>
<source/>Brain Res
          <year>2015</year>
<volume>1617</volume>
<fpage>126</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2014.04.027</pub-id>
<pub-id pub-id-type="pmid">24845720</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirschtritt</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Pauls</surname>
<given-names>DL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lifetime prevalence, age of risk, and genetic relationships of comorbid psychiatric disorders in Tourette syndrome</article-title>
<source/>JAMA psychiatry
          <year>2015</year>
<volume>72</volume>
<fpage>325</fpage>
<lpage>333</lpage>
<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2014.2650</pub-id>
<pub-id pub-id-type="pmid">25671412</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robertson</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Cavanna</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>The Gilles de la Tourette syndrome: a principal component factor analytic study of a large pedigree</article-title>
<source/>Psychiatr Genet
          <year>2007</year>
<volume>17</volume>
<fpage>143</fpage>
<lpage>152</lpage>
<pub-id pub-id-type="doi">10.1097/YPG.0b013e328015b937</pub-id>
<pub-id pub-id-type="pmid">17417057</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huisman-van Dijk</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>van de Schoot</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rijkeboer</surname>
<given-names>MM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The relationship between tics, OC, ADHD and autism symptoms: a cross-disorder symptom analysis in Gilles de la Tourette syndrome patients and family-members</article-title>
<source/>Psychiatry Res
          <year>2016</year>
<volume>237</volume>
<fpage>138</fpage>
<lpage>146</lpage>
<pub-id pub-id-type="doi">10.1016/j.psychres.2016.01.051</pub-id>
<pub-id pub-id-type="pmid">26826899</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eapen</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Snedden</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Črnčec</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tourette syndrome, co-morbidities and quality of life</article-title>
<source/>ANZ J Psychiatry
          <year>2016</year>
<volume>50</volume>
<issue>82–93</issue>
<fpage>12p</fpage>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cukier</surname>
<given-names>HN</given-names>
</name>
<name>
<surname>Dueker</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Slifer</surname>
<given-names>SH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing of extended families with autism reveals genes shared across neurodevelopmental and neuropsychiatric disorders</article-title>
<source/>Mol Autism
          <year>2014</year>
<volume>5</volume>
<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-5-1</pub-id>
<pub-id pub-id-type="pmid">24410847</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kern</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Geier</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>King</surname>
<given-names>PG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Shared brain connectivity issues, symptoms, and comorbidities in autism spectrum disorder, attention deficit/hyperactivity disorder, and Tourette syndrome</article-title>
<source/>Brain Connect
          <year>2015</year>
<volume>5</volume>
<fpage>321</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1089/brain.2014.0324</pub-id>
<pub-id pub-id-type="pmid">25602622</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Worbe</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Neuroimaging signature of neuropsychiatric disorders</article-title>
<source/>Curr Opin Neurol
          <year>2015</year>
<volume>28</volume>
<fpage>358</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="doi">10.1097/WCO.0000000000000220</pub-id>
<pub-id pub-id-type="pmid">26110796</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cominings</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Himes</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Comings</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>An epidemiologic study of Tourette’s syndrome in a single school district</article-title>
<source/>J Clin Psychiatry
          <year>1990</year>
<volume>51</volume>
<fpage>463</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="pmid">2228981</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apter</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pauls</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Bleich</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An epidemiologic study of Gilles de la Tourette’s syndrome in Israel</article-title>
<source/>Arch Gen Psychiatry
          <year>1993</year>
<volume>50</volume>
<fpage>734</fpage>
<lpage>738</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1993.01820210068008</pub-id>
<pub-id pub-id-type="pmid">8357298</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Tourette’s syndrome in Taiwan: an epidemiological study of tic disorders in an elementary school at Taipei County</article-title>
<source/>Brain Dev
          <year>2003</year>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadesjö</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Tourette’s disorder: epidemiology and comorbidity in primary school children</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>2000</year>
<volume>39</volume>
<fpage>548</fpage>
<lpage>555</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-200005000-00007</pub-id>
<pub-id pub-id-type="pmid">10802971</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khalifa</surname>
<given-names>N</given-names>
</name>
<name>
<surname>von Knorring</surname>
<given-names>A-L</given-names>
</name>
</person-group>
<article-title>Psychopathology in a Swedish population of school children with tic disorders</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>2006</year>
<volume>45</volume>
<fpage>1346</fpage>
<lpage>1353</lpage>
<pub-id pub-id-type="doi">10.1097/01.chi.0000251210.98749.83</pub-id>
<pub-id pub-id-type="pmid">17075357</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>American Psychiatric Association</collab>
</person-group>
<source/>Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR)
          <year>2000</year>
<edition>4</edition>
<publisher-loc>St. Louis</publisher-loc>
<publisher-name>American Psychiatric Association</publisher-name>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polanczyk</surname>
<given-names>GV</given-names>
</name>
<name>
<surname>Willcutt</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Salum</surname>
<given-names>GA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis</article-title>
<source/>Int J Epidemiol
          <year>2014</year>
<volume>43</volume>
<fpage>434</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1093/ije/dyt261</pub-id>
<pub-id pub-id-type="pmid">24464188</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faraone</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Sergeant</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Biederman</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The worldwide prevalence of ADHD: is it an American condition?</article-title>
<source/>World Psychiatry
          <year>2003</year>
<volume>2</volume>
<fpage>104</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="pmid">16946911</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Wayne</surname>
<given-names>HL</given-names>
</name>
</person-group>
<article-title>The symptomatology and diagnosis of Gilles de la Tourette’s syndrome</article-title>
<source/>J Am Acad Child Psychiatry
          <year>1973</year>
<volume>12</volume>
<fpage>702</fpage>
<lpage>723</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-7138(09)61277-2</pub-id>
<pub-id pub-id-type="pmid">4522107</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>RD</given-names>
</name>
</person-group>
<article-title>Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome</article-title>
<source/>Eur Child Adolesc Psychiatry.
          <year>2007</year>
<volume>16</volume>
<fpage>15</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-007-1003-7</pub-id>
<pub-id pub-id-type="pmid">17665279</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sambrani</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jakubovski</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Muller-Vahl</surname>
<given-names>KR</given-names>
</name>
</person-group>
<article-title>New insights into clinical characteristics of Gilles de la Tourette syndrome: findings in 1032 patients from a single German center</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>415</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2016.00415</pub-id>
<pub-id pub-id-type="pmid">27672357</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Debes</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Hjalgrim</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Skov</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Clinical aspects of Tourette syndrome</article-title>
<source/>Ugeskr Laeger
          <year>2008</year>
<volume>170</volume>
<fpage>2701</fpage>
<lpage>2703</lpage>
<pub-id pub-id-type="pmid">18761861</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Specht</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Piacentini</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical characteristics of children and adolescents with a primary tic disorder</article-title>
<source/>J Dev Phys Disabil
          <year>2011</year>
<volume>23</volume>
<fpage>15</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1007/s10882-010-9223-z</pub-id>
<pub-id pub-id-type="pmid">24999300</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lebowitz</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Motlagh</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Katsovich</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tourette syndrome in youth with and without obsessive compulsive disorder and attention deficit hyperactivity disorder</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2012</year>
<volume>21</volume>
<fpage>451</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-012-0278-5</pub-id>
<pub-id pub-id-type="pmid">22543961</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byler</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Lehman</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tourette syndrome: a general pediatrician’s 35-year experience at a single center with follow-up in adulthood</article-title>
<source/>Clin Pediatr (Phila)
          <year>2015</year>
<volume>54</volume>
<fpage>138</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1177/0009922814550396</pub-id>
<pub-id pub-id-type="pmid">25200367</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altarac</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saroha</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Lifetime prevalence of learning disability among US children</article-title>
<source/>Pediatrics
          <year>2007</year>
<volume>119</volume>
<issue>Suppl</issue>
<fpage>S77</fpage>
<lpage>S83</lpage>
<pub-id pub-id-type="doi">10.1542/peds.2006-2089L</pub-id>
<pub-id pub-id-type="pmid">17272589</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comings</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Comings</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Tourette’s syndrome and attention deficit disorder with hyperactivity</article-title>
<source/>Arch Gen Psychiatry
          <year>1987</year>
<volume>44</volume>
<fpage>1023</fpage>
<lpage>1026</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1987.01800230103017</pub-id>
<pub-id pub-id-type="pmid">3479057</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teive</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Germiniani</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Della Coletta</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Werneck</surname>
<given-names>LC</given-names>
</name>
</person-group>
<article-title>Tics and Tourette syndrome: clinical evaluation of 44 cases</article-title>
<source/>Arq Neuropsiquiatr
          <year>2001</year>
<volume>59</volume>
<fpage>725</fpage>
<lpage>728</lpage>
<pub-id pub-id-type="doi">10.1590/S0004-282X2001000500014</pub-id>
<pub-id pub-id-type="pmid">11593273</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeates</surname>
<given-names>KO</given-names>
</name>
<name>
<surname>Bornstein</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Neuropsychological correlates of learning disability subtypes in children with Tourette’s syndrome</article-title>
<source/>J Int Neuropsychol Soc
          <year>1996</year>
<volume>2</volume>
<fpage>375</fpage>
<lpage>382</lpage>
<pub-id pub-id-type="doi">10.1017/S1355617700001442</pub-id>
<pub-id pub-id-type="pmid">9375162</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burd</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Klug</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Kerbeshian</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Tourette syndrome and learning disabilities</article-title>
<source/>BMC Pediatr
          <year>2005</year>
<volume>5</volume>
<fpage>34</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2431-5-34</pub-id>
<pub-id pub-id-type="pmid">16137334</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Freeman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Fast</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Burd</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries</article-title>
<source/>Dev Med Child Neurol
          <year>2000</year>
<volume>42</volume>
<fpage>436</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.1017/S0012162200000839</pub-id>
<pub-id pub-id-type="pmid">10972415</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elsabbagh</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Divan</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>YJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Global prevalence of autism and other pervasive developmental disorders</article-title>
<source/>Autism Res
          <year>2012</year>
<volume>5</volume>
<fpage>160</fpage>
<lpage>179</lpage>
<pub-id pub-id-type="doi">10.1002/aur.239</pub-id>
<pub-id pub-id-type="pmid">22495912</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burd</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>WW</given-names>
</name>
<name>
<surname>Kerbeshian</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Is development of Tourette disorder a marker for improvement in patients with autism and other pervasive developmental disorders?</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1987</year>
<volume>26</volume>
<fpage>162</fpage>
<lpage>165</lpage>
<pub-id pub-id-type="doi">10.1097/00004583-198703000-00006</pub-id>
<pub-id pub-id-type="pmid">3473062</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comings</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Comings</surname>
<given-names>BG</given-names>
</name>
</person-group>
<article-title>Clinical and genetic relationships between autism-pervasive developmental disorder and Tourette syndrome: a study of 19 cases</article-title>
<source/>Am J Med Genet
          <year>1991</year>
<volume>39</volume>
<fpage>180</fpage>
<lpage>191</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.1320390213</pub-id>
<pub-id pub-id-type="pmid">2063922</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marriage</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stokes</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Davey</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Clinical and research implications of the co-occurrence of Asperger’s and Tourette syndromes</article-title>
<source/>ANZ J Psychiatry
          <year>1993</year>
<volume>27</volume>
<fpage>666</fpage>
<lpage>672</lpage>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sverd</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Montero</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gurevich</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Brief report: cases for an association between Tourette syndrome, autistic disorder, and schizophrenia-like disorder</article-title>
<source/>J Autism Dev Disord
          <year>1993</year>
<volume>23</volume>
<fpage>407</fpage>
<lpage>413</lpage>
<pub-id pub-id-type="doi">10.1007/BF01046229</pub-id>
<pub-id pub-id-type="pmid">8331056</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kano</surname>
<given-names>YO</given-names>
</name>
</person-group>
<article-title>Tourette’s disorder coupled with infantile autism: a prospective study of two boys</article-title>
<source/>Jpn J Psychiatry Neurol
          <year>1988</year>
<volume>42</volume>
<fpage>49</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">3165152</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baron-Cohen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Scahill</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Izaguirre</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The prevalence of Gilles de la Tourette syndrome in children and adolescents with autism: a large scale study</article-title>
<source/>Psychol Med
          <year>1999</year>
<volume>29</volume>
<fpage>1151</fpage>
<lpage>1159</lpage>
<pub-id pub-id-type="doi">10.1017/S003329179900896X</pub-id>
<pub-id pub-id-type="pmid">10576307</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Canitano</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Vivanti</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Tics and Tourette syndrome in autism spectrum disorders</article-title>
<source/>Autism
          <year>2007</year>
<volume>11</volume>
<fpage>19</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1177/1362361307070992</pub-id>
<pub-id pub-id-type="pmid">17175571</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burd</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Kerbeshian</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tourette syndrome and comorbid pervasive developmental disorders</article-title>
<source/>J Child Neurol
          <year>2009</year>
<volume>24</volume>
<fpage>170</fpage>
<lpage>175</lpage>
<pub-id pub-id-type="doi">10.1177/0883073808322666</pub-id>
<pub-id pub-id-type="pmid">19182154</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darrow</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Grados</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sandor</surname>
<given-names>P</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Autism spectrum symptoms in a Tourette’s disorder sample</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>2017</year>
<volume>56</volume>
<issue>610–617</issue>
<fpage>e1</fpage>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Eapen</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Pathogenetic model for Tourette syndrome delineates overlap with related neurodevelopmental disorders including autism</article-title>
<source/>Transl Psychiatry
          <year>2012</year>
<volume>2</volume>
<fpage>e158</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2012.75</pub-id>
<pub-id pub-id-type="pmid">22948383</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Willcutt</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Pennington</surname>
<given-names>BF</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Understanding the complex etiologies of developmental disorders: behavioral and molecular genetic approaches</article-title>
<source/>J Dev Behav Pediatr
          <year>2010</year>
<volume>31</volume>
<fpage>533</fpage>
<lpage>544</lpage>
<pub-id pub-id-type="doi">10.1097/DBP.0b013e3181ef42a1</pub-id>
<pub-id pub-id-type="pmid">20814254</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gillberg</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>The ESSENCE in child psychiatry: early symptomatic syndromes eliciting neurodevelopmental clinical examinations</article-title>
<source/>Res Dev Disabil
          <year>2010</year>
<volume>31</volume>
<fpage>1543</fpage>
<lpage>1551</lpage>
<pub-id pub-id-type="doi">10.1016/j.ridd.2010.06.002</pub-id>
<pub-id pub-id-type="pmid">20634041</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Volkmar</surname>
<given-names>FR</given-names>
</name>
</person-group>
<article-title>Issues in the classification of pervasive and other developmental disorders: toward DSM-IV</article-title>
<source/>J Am Acad Child Psychiatry
          <year>1986</year>
<volume>25</volume>
<fpage>213</fpage>
<lpage>220</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-7138(09)60228-4</pub-id>
<pub-id pub-id-type="pmid">3700908</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roessner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Plessen</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Rothenberger</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2011</year>
<volume>20</volume>
<fpage>173</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-011-0163-7</pub-id>
<pub-id pub-id-type="pmid">21445724</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martino</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Gilles de la Tourette syndrome—a treatable condition?</article-title>
<source/>Rev Neurol (Paris)
          <year>2016</year>
<volume>172</volume>
<fpage>446</fpage>
<lpage>454</lpage>
<pub-id pub-id-type="doi">10.1016/j.neurol.2016.07.004</pub-id>
<pub-id pub-id-type="pmid">27476415</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verdellen</surname>
<given-names>C</given-names>
</name>
<name>
<surname>van de Griendt</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions</article-title>
<source/>Eur Child Adolesc Psychiatry
          <year>2011</year>
<volume>20</volume>
<fpage>197</fpage>
<lpage>207</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-011-0167-3</pub-id>
<pub-id pub-id-type="pmid">21445725</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chee</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Sachdev</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>The clinical features of Tourette’s disorder: an Australian study using a structured interview schedule</article-title>
<source/>ANZ J Psychiatry
          <year>1994</year>
<volume>28</volume>
<fpage>313</fpage>
<lpage>318</lpage>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abwender</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Como</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Kurlan</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>School problems in Tourette’s syndrome</article-title>
<source/>Arch Neurol
          <year>1996</year>
<volume>53</volume>
<fpage>509</fpage>
<lpage>511</lpage>
<pub-id pub-id-type="doi">10.1001/archneur.1996.00550060051016</pub-id>
<pub-id pub-id-type="pmid">8660152</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cardoso</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Veado</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>de Oliveira</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>A Brazilian cohort of patients with Tourette’s syndrome</article-title>
<source/>J Neurol Neurosurg Psychiatry
          <year>1996</year>
<volume>60</volume>
<fpage>209</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1136/jnnp.60.2.209</pub-id>
<pub-id pub-id-type="pmid">8708658</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schuerholz</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Baumgardner</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>HS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropsychological status of children with Tourette’s syndrome with and without attention deficit hyperactivity disorder</article-title>
<source/>Neurology
          <year>1996</year>
<volume>46</volume>
<fpage>958</fpage>
<lpage>965</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.46.4.958</pub-id>
<pub-id pub-id-type="pmid">8780072</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wodrich</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Benjamin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lachar</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Tourette’s syndrome and psychopathology in a child psychiatry setting</article-title>
<source/>J Am Acad Child Adolesc Psychiatry
          <year>1997</year>
<volume>36</volume>
<fpage>1618</fpage>
<lpage>1624</lpage>
<pub-id pub-id-type="pmid">9394949</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kano</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nagai</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Clinical characteristics of Tourette syndrome</article-title>
<source/>Psychiatry Clin Neurosci
          <year>1998</year>
<volume>52</volume>
<fpage>51</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1819.1998.tb00972.x</pub-id>
<pub-id pub-id-type="pmid">9682933</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saccomani</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fabiana</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Manuela</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Giambattista</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Tourette syndrome and chronic tics in a sample of children and adolescents</article-title>
<source/>Brain Dev
          <year>2005</year>
<volume>27</volume>
<fpage>349</fpage>
<lpage>352</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2004.09.007</pub-id>
<pub-id pub-id-type="pmid">16023550</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Termine</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Balottin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychopathology in children and adolescents with Tourette’s syndrome: a controlled study</article-title>
<source/>Brain Dev
          <year>2006</year>
<volume>28</volume>
<fpage>69</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2005.04.006</pub-id>
<pub-id pub-id-type="pmid">15967616</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janik</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kalbarczyk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sitek</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Clinical analysis of Gilles de la Tourette syndrome based on 126 cases</article-title>
<source/>Neurol Neurochir Pol
          <year>2007</year>
<volume>41</volume>
<fpage>381</fpage>
<lpage>387</lpage>
<pub-id pub-id-type="pmid">18033637</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roessner</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Banaschewski</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Developmental psychopathology of children and adolescents with Tourette syndrome—impact of ADHD</article-title>
<source/>Eur Child Adolesc Psychiatry.
          <year>2007</year>
<volume>16</volume>
<fpage>24</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="doi">10.1007/s00787-007-1004-6</pub-id>
<pub-id pub-id-type="pmid">17665280</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robertson</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Althoff</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Hafez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pauls</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Principal components analysis of a large cohort with Tourette syndrome</article-title>
<source/>Br J Psychiatry
          <year>2008</year>
<volume>193</volume>
<fpage>31</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.107.039909</pub-id>
<pub-id pub-id-type="pmid">18700215</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghanizadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mosallaei</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Psychiatric disorders and behavioral problems in children and adolescents with Tourette syndrome</article-title>
<source/>Brain Dev
          <year>2009</year>
<volume>31</volume>
<fpage>15</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2008.03.010</pub-id>
<pub-id pub-id-type="pmid">18558469</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gorman</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Plessen</surname>
<given-names>KJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychosocial outcome and psychiatric comorbidity in older adolescents with Tourette syndrome: controlled study</article-title>
<source/>Br J Psychiatry
          <year>2010</year>
<volume>197</volume>
<fpage>36</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1192/bjp.bp.109.071050</pub-id>
<pub-id pub-id-type="pmid">20592431</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gulisano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pellico</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Tourette syndrome and comorbid conditions: a spectrum of different severities and complexities</article-title>
<source/>J Child Neurol
          <year>2014</year>
<volume>29</volume>
<fpage>1383</fpage>
<lpage>1389</lpage>
<pub-id pub-id-type="doi">10.1177/0883073814534317</pub-id>
<pub-id pub-id-type="pmid">24832397</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>